Archive for November, 2016



Immunic Acquires 4SC’s Immunology Portfolio

November 14th, 2016
Posted by

regulatory_t_cells

After announcing the the closure of Series A funding with $19.6 million, Immunic recently acquired 4SC’s immunology portfolio. The acquisition adds two promising drug development programs to the biotech startup’s portfolio to treat immune and autoimmune diseases.

Founded in 2016 by Manfred Groppel and Popper’s senior advisor, Dr. Andreas Muehler, Immunic develops pharmaceuticals in the immunology space, in particular for autoimmune diseases or diseases that have an important immunology component in their pathogenesis.

We are excited about the potential impact of this acquisition which will start with a clinical study involving Crohn’s patients, and are continuing to track these and other developments at the intersection of biotechnology and immunology.

Read more about the acquisition.

 

Posted in biomedical research | No Comments »





Solving the Value Equation for Molecular Diagnostics

November 1st, 2016
Posted by

Idea Bulb Concept Drawing on Blackboard

In this special blog post, we share insights from national genomics reimbursement expert and former Medicare medical director, Dr. Bruce Quinn, on how to create and capture value in precision medicine.


As medicine continues to become more personalized, the biggest challenges to the precision medicine market aren’t scientific, they’re economic. These barriers are drawing more attention – from payers such as United Healthcare urging MDx reimbursement reform to healthcare systems such as Cleveland Clinic which presented several views of payment redesign at their 2016 Medical Innovation Summit. A recent GenomeWeb article by Monica Heger echoed this sentiment, citing the need for partnerships and novel regulatory structures to address challenges with diagnostic test development, reimbursement, and regulation.

Read the rest of this entry »

Posted in biomedical research | No Comments »